Abstract
A compound of the general formula A or a or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is selected from the group consisting of: C1-C12-alkyl, C3-C12-cycloalkyl, C6- C10-aryl, and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3, amino, C1-C6-alkylamino, C1-C6-dialkylamino, C1C6- (halo)alkyl, C1C6-(halo)- alkoxy and/or COOR3; R2 is selected from the group consisting of: C6-C10-aryl and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3 amino, C1C6- alkylamino, CrC6-dialkyl- amino, C1-C6-(halo)alkyl, C1C6-(halo)alkoxy and/or COOR3; R3 is independently at each occurrence selected from the group consisting of hydrogen and C1-C2-alkyl; and n is an integer from 1 to 10 inclusive.
| Original language | English |
|---|---|
| Patent number | WO2016051155 A1 |
| Priority date | 29/09/14 |
| Publication status | Published - 7 Apr 2016 |
Keywords
- NEURODEGENERATIVE DISEASE
- arylalkylpiperazines
- dopamine D-2 receptors
- serotonin 5-HT1A receptors
- OXIDATIVE STRESS
Fingerprint
Dive into the research topics of 'Arylalkylpiperazines for use as neuroprotective agents: Arlyalkylpiperazines and neuroprotection'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver